Author

A. Singh

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Sotagliflozin Reprograms Hepatic Lipid Metabolism and Attenuates Atherosclerosis Beyond Empagliflozin in CKM Mice

Dual SGLT1/2 inhibition reduces atherosclerosis and metabolic syndrome more effectively than selective SGLT2 inhibition and is associated with reprogramming of hepatic lipid metabolism, suggesting that sotagliflozin could be an attractive candidate for mitigating atherosclerotic risk in non-diabetic CKD.

Keith L. Saum, Jessica Sim, L. Zeng et al. · bioRxiv · 0 citations

#protein folding Open access Aug 2026

Autotaxin Inhibition Ameliorates HFpEF Phenotype By Reducing LPA-Mediated Systemic Inflammation and Cardiac Remodeling

In male mice with established two-hit HFpEF, autotaxin inhibition improved diastolic indices and reduced fibrosis, hypertrophy and cardiac myeloid accumulation and the autotaxin–LPA axis is nominated as a tractable therapeutic target.

Rajesh Chaudhary, Andrew Robbins, A. Singh et al. · bioRxiv · 0 citations